WHO gives emergency use listing to Moderna's coronavirus vaccine

Many countries without their own advanced medical regulatory and assessment offices rely on the WHO listing to decide whether to use vaccines

Moderna
AP | PTI Geneva
2 min read Last Updated : May 01 2021 | 5:37 PM IST

The World Health Organisation has given the go-ahead for emergency use of Moderna's COVID-19 vaccine.

The mRNA vaccine from the US manufacturer joins vaccines from AstraZeneca, Pfizer-BioNTech and Johnson & Johnson in receiving the WHO's emergency use listing.

Similar approvals for China's Sinopharm and Sinovac vaccines are expected in the coming days and weeks, WHO has said.

The greenlight for Moderna's vaccine, announced late Friday, took many months because of delays that WHO faced in getting data from the manufacturer.

Many countries without their own advanced medical regulatory and assessment offices rely on the WHO listing to decide whether to use vaccines. UN children's agency UNICEF also uses the listing to deploy vaccines in an emergency like the pandemic.

The announcement, however, wasn't likely to have an immediate impact on supplies of Moderna's vaccine for the developing world. The company struck supply agreements with many rich countries, which will have already received millions of doses.

In a statement Friday, CEO Stephane Bancel said Moderna was actively participating in discussions with multilateral organisations, such as COVAX, to help protect populations around the world.

He was referring to a UN-backed programme to ship COVID-19 vaccines to many low- and middle-income countries, based on need.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: May 01 2021 | 5:35 PM IST

Next Story